New Data Reinforces Potential Of Sanofi's Sutimlimab After Shock FDA Snub
Second Positive Phase III Trial In Cold Agglutinin Disease
Having suffered a setback last year when deficiencies at a third-party manufacturer scuppered hopes of a quick US approval of sutimlimab for cold agglutinin disease, Sanofi has released more promising data on its C1s inhibitor at the European Hematology Association meeting.
